rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Alexandra Balcom

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Nuvalent; Director, Crescent Biopharma.

Every Form 4 they filed

In numbers

Trades disclosed
220
Buys
0
Sells
29
Bought
$0
Sold
$39.0M
Companies
2
Companies where not an officer
1
First trade
4 Jan 2022
Last trade
15 Jul 2026
Last filed
15 Jul 2026

Companies traded

Where they are an officer
NuvalentOfficer · Biotechnology · last 15 Jul 20260 buys · 29 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CBIO Crescent BiopharmaDirector · Biotechnology · last 2 Jun 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 15 Jul 2026NuvalentBiotechnologySEC FORM 4 Code U$5.5M44,433 at $124.00filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—37,500filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—17,500filing
15 Jul 2026filed 15 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D—41,100filing
15 Jul 2026filed 15 Jul 2026NuvalentBiotechnologySEC FORM 4 Code A—14,350 at $0.00filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—131,637filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—8,016filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—22,933filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—84,200filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—33,646filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—37,500filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—17,500filing
15 Jul 2026filed 15 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D—14,350filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—131,637filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—8,016filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—22,933filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—84,200filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—33,646filing
15 Jul 2026filed 15 Jul 2026NuvalentSEC FORM 4 Code U$5.5M44,433 at $124.00filing
15 Jul 2026filed 15 Jul 2026NuvalentSEC FORM 4 Code D—41,100filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care8
Not placed29

Buys in green, sells in red, by the company’s sector.

Related people

James E. FlynnDirector and 10% owner and Other role · Director and 10% owner and Other at Nuvalent, filing Form 4 there in the last year
Ron SquarerDirector · Director at Nuvalent, filing Form 4 there in the last year
Sapna SrivastavaDirector · Director at Nuvalent, filing Form 4 there in the last year
Grant C. BogleDirector · Director at Nuvalent, filing Form 4 there in the last year
Michael L. MeyersDirector · Director at Nuvalent, filing Form 4 there in the last year